Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharmaceuticals has started a phase II colorectal cancer trial with its drug Davanat in combination with other chemotherapies.
Subscribe to our email newsletter
The phase II trial will examine Davanat with Avastin, 5-Fluorouracil (5-FU) and Leucovorin in patients with locally advanced colorectal cancer who are unable to tolerate intensive chemotherapy with an endpoint of tumor shrinkage.
“Davanat is the first of a new class of drugs based on carbohydrate chemistry,” said David Platt, CEO of Pro-Pharmaceuticals. “When we combine the results from this front-line trial, with the very positive results from our phase I/II trials of end stage cancer patients, we believe it will conclusively prove the efficacy enhancing affect and toxicity reduction of Davanat when co-administered with chemotherapeutics and biologics to treat cancer.”
Pro-Pharmaceuticals is currently enrolling patients in two first-line phase II cancer trials and expects preliminary results in the first quarter of 2007.
Pro-Pharmaceuticals is engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases. At present, the company's product pipeline is principally focused on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs.